The significant revenue growth and pipeline progress are positive, but the widening loss and high operating expenses warrant monitoring. The successful convertible note issuance strengthens the balance sheet for upcoming commercial launches. Traders should watch for NDA submissions in 1H 2026 and commercial execution of Attruby, which showed 35% QoQ growth in Q4.
Price Chart
Executive Summary
BridgeBio Pharma reported strong 2025 financial results driven by $502.1 million in net revenue, primarily from its ATTR-CM drug Attruby, which generated $362.4 million in net product revenue. The company achieved three positive Phase 3 trial readouts, secured $632.5 million in convertible notes, and maintained a robust pipeline with multiple near-term NDA submissions. Despite revenue growth, net loss widened to $724.9 million due to increased commercial and R&D investments.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $154.2 million (up from $5.9 million YoY), full year revenue: $502.1 million (up from $221.9 million YoY)
- Attruby net product revenue: $146.0 million in Q4, $362.4 million for full year 2025
- Three positive Phase 3 readouts: BBP-418 (LGMD2IR9), encaleret (ADH1), and infigratinib (achondroplasia)
- Cash position: $587.5 million as of December 31, 2025, plus $632.5 million from January 2026 convertible notes issuance
- Net loss attributable to common stockholders: $724.9 million for 2025 (vs $535.8 million in 2024)
Financial Impact
Revenue increased by $280.2 million YoY, driven by $359.5 million growth in Attruby sales, but operating expenses rose $210.6 million to $1.0 billion
Segment Breakdown
| Segment | Revenue |
|---|---|
| Attruby | $362.4M |
Risk Factors
- Increasing operating losses despite revenue growth
- High dependence on Attruby sales with competitive risks
- Execution risk in upcoming NDA submissions and product launches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001743881-26-000008 |
| Document: bbio-20260224.htm | 0001743881-26-000008 |
| Document: 0001743881-26-000008-index-headers.html | 0001743881-26-000008 |
| Document: 0001743881-26-000008-index.html | 0001743881-26-000008 |
| Document: 0001743881-26-000008.txt | 0001743881-26-000008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access